立体定向放疗在高龄局限性肺癌患者中的疗效与安全性评估  

Effect of stereotactic body radiation therapy on non-small cell lung cancer in senile patients and its safety

作　　者：任艳萍[1] 焦玉新[1] 戈伟强[1] 张立波[1] 郑向鹏[1] 胡超苏[2] 

机构地区：[1]复旦大学附属华东医院放疗科,上海市200040 [2]复旦大学附属肿瘤医院放疗中心,上海市200032

出　　处：《老年医学与保健》2016年第6期387-390,共4页Geriatrics & Health Care

基　　金：国家自然科学基金(81472794);上海市科学技术委员会基金(24119a0400);上海市卫生与计划生育委员会基金(20134360)

摘　　要：目的评估立体定向放疗在高龄(≥75岁)局限性肺癌患者中的疗效和安全性。方法回顾分析我院近4年SBRT治疗的25例高龄局限性肺癌患者的临床资料、治疗过程、肿瘤控制率和毒性反应;分析毒性反应相关的因素。结果全部患者均按计划完成治疗,未出现中途暂停或中断治疗的情况。治疗周期内患者无明显与治疗相关不良反应。最长随访时间为37.3个月,中位随访时间17.1个月,肿瘤1年和2年局部控制率分别为93.8%和82.0%。总体肺炎发生率约为48%,肺炎范围局限。多因素回归分析显示,肺炎发生与MLD、V5和V10无统计学相关性,而与V20、V30存在较明确的相关性,P值分别为0.02和0.006。结论对于高龄局限性肺癌患者,SBRT治疗安全和有效,肿瘤局控率令人满意,治疗后患者的生活质量未受明显影响。Objective To assess the effect of stereotactic body radiation therapy （SBRT） on non-small cell lung cancer （NSCLC） in senile patients and the safety. Methods A retrospective analysis was made to the clinical data of 25 senile patients with NSCLC, including the therapeutic process, tumor local control and toxicity, and the related factors to toxicity was studied. Results All patients completed the planned radiotherapy without interruption or cancelation and no evident treatment-related side effect was found during the radiotherapy course; the longest follow-up lasted for 37.3 months and the median follow-up period was 17.1 months （1.3-37.3 months）; the 1-year and 2-year LC was 93.8% and 82.0%; the gross incidence of RP was 48 % and the extent of RP was limited; Multiple-variable regression analysis showed there existed no correlation of statistical significance between RP and V5 and V10 but an obvious correlation between RP and V20 （P=0.02） and V30 （P=0.006）. Conclusions SBRT is safe and effective with satisfactory LC for senile patients with NSCLC, which leaves no impact on life quality of the patients.

关 键 词：老年 肺癌 立体定向放射治疗 

分 类 号：R734.2[医药卫生—肿瘤]